{
  "ticker": "CHM",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959004",
  "id": "02959004",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250617",
  "time": "0829",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250617/pdf/06kt6st9534k2w.pdf",
  "summary": "### Summary:  \n- **Clinical Trial Update**: Translational data shows CHM CDH17 CAR-T cells persist for up to **six months** post-infusion in two subjects at **Dose Level 1** (out of 4).  \n- **Target Validation**: CDH17 (cadherin 17) confirmed on tumour cells in all subjects.  \n- **Trial Progress**: **Dose Level 2** enrollment ongoing; Phase 1/2 trial (NCT06055439) aims to enroll up to **15 patients** for dose selection.  \n\n**No material trading or capital markets information identified.**",
  "usage": {
    "prompt_tokens": 1278,
    "completion_tokens": 129,
    "total_tokens": 1407,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-16T22:55:18.202592"
}